1. Home
  2. RPTX
  3. RPTX News

Latest Repare Therapeutics Inc. (RPTX) News on October 26, 2025

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
RPTX

GlobeNewswire

9 days ago

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

RPTX

Business Wire

12 days ago

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RPTX

Business Wire

5 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

Repare signs out-licensing deal with DCx Biotherapeutics
RPTX

Pharmaceutical Technology

6 months ago

Repare signs out-licensing deal with DCx Biotherapeutics

RPTX

Business Wire

6 months ago

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

RPTX

Business Wire

6 months ago

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

RPTX

MT Newswires

7 months ago

Repare Therapeutics Appoints Steve Forte as CEO to Succeed Lloyd Segal

RPTX

Business Wire

7 months ago

Repare Therapeutics Announces Leadership Transitions

What Makes Repare Therapeutics (RPTX) a New Buy Stock
RPTX

Zacks

8 months ago

What Makes Repare Therapeutics (RPTX) a New Buy Stock

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RPTX

Business Wire

8 months ago

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
RPTX

Simply Wall St.

8 months ago

Here's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

Repare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
RPTX

Simply Wall St.

8 months ago

Repare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
RPTX

Business Wire

8 months ago

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

RPTX

MT Newswires

8 months ago

Repare Therapeutics Chief Medical Officer to Leave

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
RPTX

Zacks

8 months ago

Myriad Genetics (MYGN) Meets Q4 Earnings Estimates

Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
RPTX

Zacks

9 months ago

Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
RPTX

Zacks

9 months ago

Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

RPTX

MT Newswires

10 months ago

Repare Therapeutics to Refocus Resources on Advancing 2 Phase 1 Clinical Trials

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
RPTX

Business Wire

10 months ago

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

RPTX

MT Newswires

10 months ago

Top Midday Decliners

Why Is Repare Therapeutics Stock Trading Lower On Friday?
RPTX

Benzinga

10 months ago

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results
RPTX

GuruFocus.com

10 months ago

Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results

Repare Therapeutics eyes Phase III cancer study after Mythic trial success
RPTX

Clinical Trials Arena

10 months ago

Repare Therapeutics eyes Phase III cancer study after Mythic trial success

RPTX

MT Newswires

10 months ago

Top Premarket Decliners

RPTX

MT Newswires

10 months ago

Repare Therapeutics Shares Fall as Phase 1 Trial Results for Cancer Drugs Disappoint Investors

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
RPTX

Business Wire

10 months ago

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
RPTX

Business Wire

a year ago

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts
RPTX

Simply Wall St.

a year ago

Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
RPTX

Business Wire

a year ago

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
RPTX

Business Wire

a year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Repare Therapeutics’ individualised anaemia management trial shows promise
RPTX

Clinical Trials Arena

a year ago

Repare Therapeutics’ individualised anaemia management trial shows promise

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
RPTX

Business Wire

a year ago

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
RPTX

Zacks

a year ago

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug

Repare Therapeutics doses first subject in Phase I solid tumour trial
RPTX

Clinical Trials Arena

a year ago

Repare Therapeutics doses first subject in Phase I solid tumour trial

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
RPTX

Business Wire

a year ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
RPTX

Business Wire

a year ago

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company
RPTX

Simply Wall St.

a year ago

Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
RPTX

Business Wire

a year ago

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

RPTX

Business Wire

a year ago

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets
RPTX

Clinical Trials Arena

a year ago

Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets

Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets
RPTX

Pharmaceutical Technology

a year ago

Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets

Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic Landscape
RPTX

Insider Monkey

a year ago

Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic Landscape

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
RPTX

Business Wire

a year ago

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Repare Therapeutics to Participate in Two Upcoming Investor Conferences
RPTX

Business Wire

a year ago

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
RPTX

Zacks

a year ago

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
RPTX

Business Wire

a year ago

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
RPTX

Simply Wall St.

a year ago

We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
RPTX

Zacks

a year ago

Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?

Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund
RPTX

CNW Group

a year ago

Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund

RPTX

MT Newswires

a year ago

Repare Therapeutics Says Lunresertib With Folfiri Shows 'Promising' Efficacy, Tolerability in Phase 1 Solid Tumor Study

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
RPTX

Business Wire

a year ago

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

RPTX

MT Newswires

a year ago

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion Trial

RPTX

Business Wire

a year ago

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

RPTX

Business Wire

a year ago

Net Asset Value(s)

GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials
RPTX

GlobeNewswire

a year ago

GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials

[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
RPTX

GlobeNewswire

a year ago

[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

CCF Group Successful €225m AT1 Issuance
RPTX

Business Wire

a year ago

CCF Group Successful €225m AT1 Issuance

Should You Hold 908 Devices (MASS)?
RPTX

Insider Monkey

a year ago

Should You Hold 908 Devices (MASS)?

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028
RPTX

GlobeNewswire

a year ago

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028

3 Major Product Releases at 3Shape Discover Event
RPTX

PR Newswire

a year ago

3 Major Product Releases at 3Shape Discover Event

Calculating The Fair Value Of Mincon Group plc (LON:MCON)
RPTX

Simply Wall St.

a year ago

Calculating The Fair Value Of Mincon Group plc (LON:MCON)

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
RPTX

Zacks

a year ago

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag

RPTX

MT Newswires

a year ago

Repare Therapeutics Gets Fast-Track Designation for Cancer Treatment Combo Candidate

RPTX

Business Wire

a year ago

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

RPTX

Business Wire

a year ago

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

RPTX

Business Wire

a year ago

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Need To Know: Analysts Are Much More Bullish On Repare Therapeutics Inc. (NASDAQ:RPTX)
RPTX

Simply Wall St.

a year ago

Need To Know: Analysts Are Much More Bullish On Repare Therapeutics Inc. (NASDAQ:RPTX)

Repare Therapeutics First Quarter 2024 Earnings: Beats Expectations
RPTX

Simply Wall St.

a year ago

Repare Therapeutics First Quarter 2024 Earnings: Beats Expectations

RPTX

MT Newswires

a year ago

Top Premarket Gainers

RPTX

Business Wire

a year ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
RPTX

Business Wire

a year ago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

RPTX

Business Wire

a year ago

Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition

RPTX

Business Wire

a year ago

Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the brunt
RPTX

Simply Wall St.

2 years ago

Repare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the brunt

Repare Therapeutics Full Year 2023 Earnings: Misses Expectations
RPTX

Simply Wall St.

2 years ago

Repare Therapeutics Full Year 2023 Earnings: Misses Expectations

RPTX

Business Wire

2 years ago

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023
RPTX

GuruFocus.com

2 years ago

Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023

RPTX

Business Wire

2 years ago

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
RPTX

Zacks

2 years ago

Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

We're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Rate
RPTX

Simply Wall St.

2 years ago

We're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Rate

RPTX

Business Wire

2 years ago

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
RPTX

Zacks

2 years ago

Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?

RPTX

Business Wire

2 years ago

Repare Therapeutics to Regain Global Rights to Camonsertib

RPTX

Thomson Reuters StreetEvents

2 years ago

Q1 2024 Clearfield Inc Earnings Call

Clearfield, Inc. (NASDAQ:CLFD) Q1 2024 Earnings Call Transcript
RPTX

Insider Monkey

2 years ago

Clearfield, Inc. (NASDAQ:CLFD) Q1 2024 Earnings Call Transcript

Clearfield (CLFD) Reports Q1 Loss, Tops Revenue Estimates
RPTX

Zacks

2 years ago

Clearfield (CLFD) Reports Q1 Loss, Tops Revenue Estimates

Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
RPTX

Zacks

2 years ago

Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm

RPTX

GlobeNewswire

2 years ago

Southern California Bancorp and California BanCorp Announce a Merger of Equals to Create a Premier California Business Bank

Southern Missouri Bancorp (SMBC) Misses Q2 Earnings and Revenue Estimates
RPTX

Zacks

2 years ago

Southern Missouri Bancorp (SMBC) Misses Q2 Earnings and Revenue Estimates

Ur-Energy Provides 2023 Q4/YE Operations Update
RPTX

ACCESSWIRE

2 years ago

Ur-Energy Provides 2023 Q4/YE Operations Update

loanDepot President and CEO Frank Martell recognized among Inman’s 2024 "Power Players" for second consecutive year
RPTX

Business Wire

2 years ago

loanDepot President and CEO Frank Martell recognized among Inman’s 2024 "Power Players" for second consecutive year

FTC sues to block Novant purchase of two CHS hospitals
RPTX

Healthcare Dive

2 years ago

FTC sues to block Novant purchase of two CHS hospitals

Home Bancorp, Inc. (NASDAQ:HBCP) Q4 2023 Earnings Call Transcript
RPTX

Insider Monkey

2 years ago

Home Bancorp, Inc. (NASDAQ:HBCP) Q4 2023 Earnings Call Transcript

Clean Earth and Veolia North America Sign First-of-its-Kind Hazardous Waste Treatment Agreement
RPTX

Business Wire

2 years ago

Clean Earth and Veolia North America Sign First-of-its-Kind Hazardous Waste Treatment Agreement

RPTX

Business Wire

2 years ago

Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment

RPTX

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Old National Bancorp Earnings Call

Why RBB Bancorp Stock Bumped Higher Today
RPTX

Motley Fool

2 years ago

Why RBB Bancorp Stock Bumped Higher Today

RBB Bancorp (RBB) Reports Increased Earnings and Strategic Initiatives in Q4 and Fiscal Year 2023
RPTX

GuruFocus.com

2 years ago

RBB Bancorp (RBB) Reports Increased Earnings and Strategic Initiatives in Q4 and Fiscal Year 2023

Is Alpha Metallurgical Resources (AMR) Outperforming Other Basic Materials Stocks This Year?
RPTX

Zacks

2 years ago

Is Alpha Metallurgical Resources (AMR) Outperforming Other Basic Materials Stocks This Year?

Software Development Stocks Q3 Teardown: GitLab (NASDAQ:GTLB) Vs The Rest
RPTX

StockStory

2 years ago

Software Development Stocks Q3 Teardown: GitLab (NASDAQ:GTLB) Vs The Rest

Share on Social Networks: